VIM
AXSM icon

VELA Investment Management’s Axsome Therapeutics AXSM Stock Holding History

VELA Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,000
Closed -$338K – 171
2026
Q1 		$338K Sell
2,000
-2,000
-50% -$345K 0.08% 157
2025
Q4 		$731K Buy
4,000
+1,000
+33% +$140K 0.17% 137
2025
Q3 		$364K Buy
+3,000
New +$338K 0.09% 151

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

VELA Investment Management's AXSM Position: Q2 2026 in Review

VELA Investment Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,200 shares worth $294K. The stake represents 0.06% of the portfolio and ranks #157 among its holdings.

120 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • VELA Investment Management held 1,200 shares of Axsome Therapeutics worth $294K as of Q2 2026.
  • Axsome Therapeutics was a new VELA Investment Management position in Q2 2026.
  • Axsome Therapeutics made up 0.06% of VELA Investment Management's portfolio in Q2 2026, its #157 holding.
  • 120 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on VELA Investment Management's 13F filing for Q2 2026, filed 3 Aug 2026.